Floatz logo

Corpril

Hypertensive Disorder

University of MichiganSmall moleculePhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
67/ 100
Competitive Position
81/ 100

Competitive context

33 Active assets in the Hypertensive Disorder cohort.

View all 50

Same molecule, other indications

Corpril is also rated in:

coronary atherosclerosisDormant
BB
Indicative · Phase 4
64 / 100
View asset →
iatrogenicDormant
BB
Indicative · Phase 4
64 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
B
Indicative · Phase 4
63 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →